Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;26(6):475-480.
doi: 10.1007/s11916-022-01047-5. Epub 2022 Mar 30.

CGRP in Childhood and Adolescence Migraine: (Patho)physiological and Clinical Aspects

Stefan Evers  1   2
Affiliations
Review

CGRP in Childhood and Adolescence Migraine: (Patho)physiological and Clinical Aspects

Stefan Evers. Curr Pain Headache Rep. 2022 Jun.

Abstract

Purpose of review: To summarise and analyse the current knowledge of CGRP metabolism in childhood and adolescence and its role in childhood and adolescence migraine.

Recent findings: Influencing CGRP pathways is nowadays one of the main mechanisms to treat migraine. In adults, several clinical trials with different drug classes have supported this finding. However, only very little is known on these mechanisms in children and adolescents with migraine. Based on a literature search, it can be concluded that substantial parts of the CGRP pathways are already developed and working in the preterm fetus of animals. Newborn animals show high CGRP levels and high density of CGRP positive neurons and nerve fibres. In human studies, increased levels of CGRP were observed in childhood and adolescent migraine patients. Remedies based on influencing CGRP metabolism are also working in that age group. For triptans, this has clearly been shown; for gepants, no data are available, and for CGRP ligand/receptor antibodies, positive evidence is only available from case series. Only very little is known on CGRP metabolism in childhood and adolescence. However, placebo-controlled clinical trials both on CGRP antagonists and on CGRP ligand/receptor antibodies are under way and will show in some years whether these drug classes are efficacious also in children and adolescents.

Keywords: Antibodies; Calcitonin gene-related peptide (CGRP); Gepants; Migraine; Triptans.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest. This manuscript was not supported by any company or other commercial influences. The author is speaking for and member of advisory boards for the following companies (past three years): Lilly; Lundbeck; Novartis; Perfood; Teva.

References

    1. Dong YL, Vegiraju S, Chauhan M, Yallampalli C. Expression of calcitonin gene-related peptide receptor components, calcitonin receptor-like receptor and receptor activity modifying protein 1, in the rat placenta during pregnancy and their cellular localization. Mol Hum Reprod. 2003;9:481–490. doi: 10.1093/molehr/gag058. - DOI - PubMed
    1. Dong YL, Vegiraju S, Gangula PR, et al. Expression and regulation of calcitonin gene-related peptide receptor in rat placentas. Biol Reprod. 2002;67:1321–1326. doi: 10.1093/biolreprod/67.4.1321. - DOI - PubMed
    1. Parida SK, Schneder DB, Stoss TD, et al. Elevated circulating calcitonin gene-related peptide in umbilical cord and infant blood associated with maternal and neonatal sepsis and shock. Pediatr Res. 1998;43:276–282. doi: 10.1203/00006450-199802000-00020. - DOI - PubMed
    1. Dhall U, Cowen T, Haven AJ, Burnstock G. Perivascular noradrenergic and peptidecontaining nerves show different patterns of changes during development and ageing in the guinea-pig. J Auton Nerv Syst. 1986;16:109–126. doi: 10.1016/0165-1838(86)90003-2. - DOI - PubMed
    1. Connat JL, Busseuil D, Gambert S, Ody M, Tebaldini M, Gamboni S, Faivre B, Quiquerez AL, Millet M, Michaut P, Rochette L. Modification of the rat aortic wall during ageing: possible relation with decrease of peptidergic innervation. Anat Embryol. 2001;204:455–468. doi: 10.1007/s429-001-8002-0. - DOI

MeSH terms

Substances